|Articles|March 31, 2016

PE eBook Series 2016 Info Sheet

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe

Related Content

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

ByNicholas Jacobus

June 15th 2026

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

ByNicholas Jacobus

June 15th 2026

How Regulatory Shifts are Impacting the Vaccine Environment

ByMike Hollan,Silvia Taylor

June 15th 2026

Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim,

What Do You See as The Next Phase of Obesity Innovation?

ByNicholas Jacobus,Brian Hilberdink

June 15th 2026

Addressing Prohibitive Costs for Rare Diseases

ByMike Hollan,Lisa Bollinger

June 15th 2026

PE eBook Series 2016 Info Sheet

Related Content

Pharmaceutical Executive Daily: FDA Approves Two Indications of Keytruda in Combination with Welireg

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

How Regulatory Shifts are Impacting the Vaccine Environment

What Do You See as The Next Phase of Obesity Innovation?

Addressing Prohibitive Costs for Rare Diseases

Trending on PharmExec

How Regulatory Shifts are Impacting the Vaccine Environment

Pharma Roundup: FDA Approves Truqap Plus Abiraterone and Prednisone, FDA Approves Keytruda and Keytruda Qlex Each in Combination with Welireg

What Do You See as The Next Phase of Obesity Innovation?

Addressing Prohibitive Costs for Rare Diseases

Kardigan Planning for $350 Million IPO Raise: Report